OA
REGN icon

Oracle Alpha’s Regeneron Pharmaceuticals REGN Stock Holding History

Oracle Alpha’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$528K Sell
549
-144
-21% -$137K 0.95% 14
2023
Q4 		$609K Buy
+693
New +$571K 0.79% 19

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Oracle Alpha's REGN Position: Q1 2024 in Review

Oracle Alpha reduced its Regeneron Pharmaceuticals (REGN) stake by 21% in Q1 2024, selling an estimated $137K and leaving 549 shares worth $528K. The position accounts for 0.95% of the portfolio, ranked #14.

Oracle Alpha first reported a position in REGN in Q4 2023 and has held it in 2 quarters since. The position peaked at $609K in Q4 2023. 1,310 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Oracle Alpha held 549 shares of Regeneron Pharmaceuticals worth $528K as of Q1 2024.
  • Oracle Alpha sold 144 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $137K.
  • Regeneron Pharmaceuticals made up 0.95% of Oracle Alpha's portfolio in Q1 2024, its #14 holding.
  • Oracle Alpha first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • Oracle Alpha's Regeneron Pharmaceuticals position peaked at $609K in Q4 2023.
  • 1,310 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.